Accès gratuit
Numéro
Med Sci (Paris)
Volume 18, Numéro 3, Mars 2002
Page(s) 335 - 342
Section M/S Revues : Articles de Synthèse
DOI http://dx.doi.org/10.1051/medsci/2002183335
Publié en ligne 15 mars 2002
  1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340 : 745–50.
  2. Shiratori Y, Shiina S, Imamura M, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology 1995; 22 : 1027–33.
  3. Tsai J, Jeng J, Ho M, et al. Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br J Cancer 1997; 76 : 968–74.
  4. De Mitri MS, Poussin K, Baccarini P, et al. HCV-associated liver cancer without cirrhosis. Lancet 1995; 345 : 413–5.
  5. Grando-Lemaire V, Guettier C, Chevret S, Beaugrand M, Trinchet JC. Hepatocellular carcinoma without cirrhosis in the West: epidemiological factors and histopathology of the non-tumorous liver. Groupe d’étude et de traitement du carcinome hépatocellulaire. J Hepatol 1999; 31 : 508–13.
  6. Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47 : 131–6.
  7. Paradis V, Laurendeau I, Vidaud M, Bedossa P. Clonal analysis of macronodules in cirrhosis. Hepatology 1998; 28 : 953–8.
  8. Debuire B, Paterlini P, Pontisso P, Basso G, May E. Analysis of the p53 gene in European hepatocellular carcinomas and hepatoblastomas. Oncogene 1993; 8 : 2303–6.
  9. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350 : 427–8.
  10. Caruso ML, Valentini AM. Overexpression of p53 in a large series of patients with hepatocellular carcinoma: a clinicopathological correlation. Anticancer Res 1999; 19 : 3853–6
  11. Laurent-Puig P, Legoix P, Bluteau O, et al. Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology 2001; 120 : 1763–73.
  12. Kawai H, Suda T, Aoyagi Y, et al. Quantitative evaluation of genomic instability as a possible predictor for development of hepatocellular carcinoma: comparison of loss of heterozygosity and replication error. Hepatology 2000; 31 : 1246–50.
  13. Kusano N, Shiraishi K, Kubo K, Oga A, Okita K, Sasaki K. Genetic aberrations detected by comparative genomic hybridization in hepatocellular carcinomas: their relationship to clinicopathological features. Hepatology 1999; 29 : 1858–62.
  14. Okabe H, Ikai I, Matsuo K, et al. Comprehensive allelotype study of hepatocellular carcinoma: potential differences in pathways to hepatocellular carcinoma between hepatitis B virus-positive and -negative tumors. Hepatology 2000; 31 : 1073–9.
  15. de La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 1998; 95 : 8847–51.
  16. Kozyraki R, Scoazec JY, Flejou JF, et al. Expression of cadherins and alpha-catenin in primary epithelial tumors of the liver. Gastroenterology 1996; 110 : 1137–49.
  17. Bukh J , Purcell RH, Miller RH. Sequence analysis of the core gene of 14 hepatitis C virus genotypes. Proc Natl Acad Sci USA 1994; 91 : 8239–43.
  18. Cerino A, Boender P, La Monica N, Rosa C, Habets W, Mondelli MU. A human monoclonal antibody specific for the N terminus of the hepatitis C virus nucleocapsid protein. J Immunol 1993; 151 : 7005–15.
  19. Barba G, Harper T, Harada M, et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci USA 1997; 94 : 1200–5.
  20. Sabile A, Perlemuter G, Bono F, et al. Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. Hepatology 1999; 30 : 1064–76.
  21. Chen CM, You LR, Hwang LH, Lee YH. Direct interaction of hepatitis C virus core protein with the cellular lymphotoxin-beta receptor modulates the signal pathway of the lymphotoxin-beta receptor. J Virol 1997; 71 : 9417–26.
  22. Zhu N , Khoshnan A , Schneider R , et al. Hepatitis C virus core protein binds to the cytoplasmic domain of tumor necrosis factor (TNF) receptor 1 and enhances TNF-induced apoptosis. J Virol 1998; 72 : 3691–7.
  23. Jin DY, Wang HL, Zhou Y, et al. Hepatitis C virus core protein-induced loss of LZIP function correlates with cellular transformation. EMBO J 2000; 19 : 729–40.
  24. Ray RB, Steele R, Meyer K, Ray R. Transcriptional repression of p53 promoter by hepatitis C virus core protein. J Biol Chem 1997; 272 : 10983–6.
  25. Ray RB, Steele R, Meyer K, Ray R. Hepatitis C virus core protein represses p21waf1/Cip1/Sid1 promoter activity. Gene 1998; 208 : 331–6.
  26. Kozyraki R, Scoazec JY, Flejou JF, et al. Expression of cadherins and alpha-catenin in primary epithelial tumors of the liver. Gastroenterology 1996; 110 : 1137–49.
  27. Lu W, Lo SY, Chen M, Wu KJ, Fung YK, Ou JH. Activation of p53 tumor suppressor by hepatitis C virus core protein. Virology 1999; 264 : 134–41.
  28. Shi YZ, Hui AM, Takayama T, Li X, Cui X, Makuuchi M. Reduced p21(Waf1/Cips1) protein expression is predominantly related to altered p53 in hepatocellular carcinomas. Br J Cancer 2000; 83 : 50–5.
  29. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999; 285 : 107–10.
  30. Borowski P, Oehlman K, Heiland M, Laufs R. Nonstructural protein 3 of hepatitis C virus blocks the distribution of the free catalytic subunit of cyclic AMP-dependent protein kinase. J Virol 1997; 71 : 2838–43.
  31. Gale MJ, Korth M, Tang NM, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 230 : 217–27.
  32. Majumder M, Ghosh AK, Steele R, Ray R, Ray RB. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol 2001; 75 : 1401–7.
  33. Sakamuro D, Furukawa T, Takegami T. Hepatitis C virus nonstructural protein NS3 transforms NIH 3T3 cells. J Virol 1995; 69 : 3893–6.
  34. Moriya K, Yotsuyanagi H, Shintani Y, et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997; 78 : 1527–31.
  35. Hiramatsu N, Hayashi N, Katayama K, et al. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology 1994; 19 : 1354–9.
  36. Marusawa H, Hijikata M, Chiba T, Shimotohno K. Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-kappaB activation. J Virol 1999; 73 : 4713–20.
  37. Yoshida H, Kato N, Shiratori Y, et al. Hepatitis C virus core protein activates NF-κB-dependent signaling through tumor necrosis factor receptor-associated factor. J Biol Chem 2001; 212 : 451–62.
  38. Honda M, Kaneko S, Kawai H, Shirota Y, Kobayashi K. Differential gene expression between chronic hepatitis B and C hepatic lesion. Gastroenterology 2001; 120 : 955–66.
  39. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med 1995; 122 : 161–8.
  40. Ruster B, Zeuzem S, Roth WK. Hepatitis C virus sequences encoding truncated core proteins detected in a hepatocellular carcinoma. Biochem Biophys Res Commun 1996; 219 : 911–5.
  41. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346 : 1051–5.